Invivyd, Inc. 8-KCurrent Reports (8-K / ad hoc)

Legal Proceedings

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On July 23, 2026, Invivyd, Inc. (the “Company”) received a deficiency letter (the “ Letter”) from the Nasdaq Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for a period of 30 consecutive business days, the bid price for the Company’s common stock, $0.0001 par value per share (the “Common Stock”), had closed below the $1.00 per share minimum required for continued listing on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). The Letter has no immediate effect on the listing of the Common Stock, which continues to trade on The Nasdaq Global Market under the symbol “IVVD” at this time. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has until January 19, 2027 to regain compliance with the Minimum Bid Price Requirement (the “Initial Compliance Period”). To regain compliance, the closing bid price for the Common Stock must be at least $1.00 per share for a minimum of ten consecutive business days during the Initial Compliance Period, unless the Staff exercises its discretion to extend this ten-day period pursuant to Nasdaq Listing Rule 5810(c)(3)(H). If the Company does not regain compliance with the Minimum Bid Price Requirement by January 19, 2027, the Company may be eligible for an additional 180 calendar day period to regain compliance (the “Second Compliance Period”). To qualify for the Second Compliance Period, the Company would be required to transfer to The Nasdaq Capital Market (the “Capital Market”) and meet the continued listing requirement for market value of publicly held shares on the Capital Market and all other applicable requirements for initial listing on the Capital Market, except for the Capital Market’s bid price requirement . In addition, the Company would be required to notify Nasdaq of its intent to cure the deficiency during the Second Compliance Period. As part of its review process to determine whether the Second Compliance Period would be granted to the Company , the Staff would make a determination about whether it believes the Company will be able to cure the deficiency. If the Staff concludes that the Company will not be able to cure the deficiency, or if the Company does not rega